Maven Securities’s Vertex Pharmaceuticals VRTX Stock Holding History

Maven Securities’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1,600	Closed	-$651K	–	989
2023 Q4	$651K	Sell	1,600 -3,800	-70%	-$1.4M	0.01%	587
2023 Q3	$1.88M	Buy	+5,400	New	+$1.89M	0.02%	421
2022 Q3	–	Sell	-1,800	Closed	-$507K	–	1235
2022 Q2	$507K	Buy	+1,800	New	+$482K	0.02%	569
2021 Q4	–	Sell	-1,300	Closed	-$236K	–	1168
2021 Q3	$236K	Buy	1,300 +100	+8%	+$19.5K	0.01%	918
2021 Q2	$242K	Sell	1,200 -2,500	-68%	-$523K	0.01%	893
2021 Q1	$795K	Buy	+3,700	New	+$813K	0.04%	496
2020 Q4	–	Sell	-8,000	Closed	-$2.19M	–	870
2020 Q3	$2.19M	Buy	8,000 +2,900	+57%	+$800K	0.18%	124
2020 Q2	$1.48M	Buy	5,100 +3,600	+240%	+$976K	0.1%	166
2020 Q1	$357K	Buy	1,500 +500	+50%	+$115K	0.04%	208
2019 Q4	$217K	Buy	+1,000	New	+$202K	0.02%	336

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Maven Securities's VRTX Position: Q1 2022 in Review

Maven Securities sold out of Vertex Pharmaceuticals (VRTX) in Q1 2022, closing a stake of 3,588 shares — an estimated $788K sold.

Maven Securities first reported a position in VRTX in Q4 2016 and held it in 7 quarters. The position peaked at $931K in Q1 2021. 1,073 funds tracked by Wall St. Rank hold VRTX as of Q1 2022.

Maven Securities reported no remaining Vertex Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Maven Securities sold 3,588 Vertex Pharmaceuticals shares in Q1 2022, an estimated $788K.
Maven Securities first reported a position in Vertex Pharmaceuticals in Q4 2016 and held it in 7 quarters.
Maven Securities's Vertex Pharmaceuticals position peaked at $931K in Q1 2021.
1,073 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2022.

Based on Maven Securities's 13F filing for Q1 2022, filed 16 May 2022.